S&P 500   4,313.42 (+0.45%)
DOW   33,878.15 (+0.13%)
QQQ   355.67 (+0.71%)
AAPL   181.30 (+0.40%)
MSFT   327.02 (+0.54%)
META   263.87 (-0.27%)
GOOGL   122.90 (+0.62%)
AMZN   125.14 (+0.72%)
TSLA   247.25 (+5.28%)
NVDA   391.01 (+1.53%)
NIO   8.16 (+4.75%)
BABA   85.49 (-0.75%)
AMD   124.58 (+2.92%)
T   15.98 (-0.56%)
F   13.85 (+1.99%)
MU   66.00 (+1.04%)
CGC   0.69 (-0.56%)
GE   106.30 (+0.22%)
DIS   92.48 (-0.05%)
AMC   4.69 (+0.21%)
PFE   39.09 (+0.00%)
PYPL   63.25 (-1.54%)
NFLX   417.72 (+2.04%)
S&P 500   4,313.42 (+0.45%)
DOW   33,878.15 (+0.13%)
QQQ   355.67 (+0.71%)
AAPL   181.30 (+0.40%)
MSFT   327.02 (+0.54%)
META   263.87 (-0.27%)
GOOGL   122.90 (+0.62%)
AMZN   125.14 (+0.72%)
TSLA   247.25 (+5.28%)
NVDA   391.01 (+1.53%)
NIO   8.16 (+4.75%)
BABA   85.49 (-0.75%)
AMD   124.58 (+2.92%)
T   15.98 (-0.56%)
F   13.85 (+1.99%)
MU   66.00 (+1.04%)
CGC   0.69 (-0.56%)
GE   106.30 (+0.22%)
DIS   92.48 (-0.05%)
AMC   4.69 (+0.21%)
PFE   39.09 (+0.00%)
PYPL   63.25 (-1.54%)
NFLX   417.72 (+2.04%)
S&P 500   4,313.42 (+0.45%)
DOW   33,878.15 (+0.13%)
QQQ   355.67 (+0.71%)
AAPL   181.30 (+0.40%)
MSFT   327.02 (+0.54%)
META   263.87 (-0.27%)
GOOGL   122.90 (+0.62%)
AMZN   125.14 (+0.72%)
TSLA   247.25 (+5.28%)
NVDA   391.01 (+1.53%)
NIO   8.16 (+4.75%)
BABA   85.49 (-0.75%)
AMD   124.58 (+2.92%)
T   15.98 (-0.56%)
F   13.85 (+1.99%)
MU   66.00 (+1.04%)
CGC   0.69 (-0.56%)
GE   106.30 (+0.22%)
DIS   92.48 (-0.05%)
AMC   4.69 (+0.21%)
PFE   39.09 (+0.00%)
PYPL   63.25 (-1.54%)
NFLX   417.72 (+2.04%)
S&P 500   4,313.42 (+0.45%)
DOW   33,878.15 (+0.13%)
QQQ   355.67 (+0.71%)
AAPL   181.30 (+0.40%)
MSFT   327.02 (+0.54%)
META   263.87 (-0.27%)
GOOGL   122.90 (+0.62%)
AMZN   125.14 (+0.72%)
TSLA   247.25 (+5.28%)
NVDA   391.01 (+1.53%)
NIO   8.16 (+4.75%)
BABA   85.49 (-0.75%)
AMD   124.58 (+2.92%)
T   15.98 (-0.56%)
F   13.85 (+1.99%)
MU   66.00 (+1.04%)
CGC   0.69 (-0.56%)
GE   106.30 (+0.22%)
DIS   92.48 (-0.05%)
AMC   4.69 (+0.21%)
PFE   39.09 (+0.00%)
PYPL   63.25 (-1.54%)
NFLX   417.72 (+2.04%)
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Earnings Date, Estimates & Call Transcripts

$1.74
-0.02 (-0.85%)
(As of 09:34 AM ET)
Compare
Today's Range
$1.72
▼
$1.74
50-Day Range
$1.67
▼
$2.32
52-Week Range
$0.68
▼
$3.85
Volume
11,558 shs
Average Volume
918,825 shs
Market Capitalization
$140.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.35
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Aug. 3Estimated
Actual EPS
(Mar. 29)
-$0.16 Beat By $0.04
Consensus EPS
(Mar. 29)
-$0.20
Last Year's Q1 EPS
(2/24/2022)
-$0.30
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PRQR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PRQR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ProQR Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($0.17)($0.17)($0.17)
Q2 20231($0.14)($0.14)($0.14)
Q3 20231($0.14)($0.14)($0.14)
Q4 20231$0.36$0.36$0.36
FY 20234($0.09)($0.09)($0.09)

PRQR Earnings Date and Information

ProQR Therapeutics last released its quarterly earnings results on March 29th, 2023. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The firm had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1 million. ProQR Therapeutics has generated ($0.84) earnings per share over the last year (($0.84) diluted earnings per share). Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.47) per share. ProQR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off prior year's report dates.

ProQR Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/3/2023
(Estimated)		        
3/29/2023Q4 2022($0.20)($0.16)+$0.04($0.16)$1.00 million$0.84 million
11/9/2022Q3 2022($0.23)($0.34)($0.11)($0.34)$1.05 million$0.96 million
8/4/2022Q2 2022($0.26)($0.22)+$0.04($0.22)$1.21 million$1.09 million
5/5/2022Q1 2022($0.25)($0.22)+$0.03($0.22)$1.19 million$1.39 million
2/24/2022Q4 2021($0.26)($0.30)($0.04)($0.30)$0.90 million$0.27 million    
11/4/20219/30/2021($0.21)($0.22)($0.01)($0.26)$0.80 million$1.03 million
8/5/20216/30/2021($0.21)($0.24)($0.03)($0.29)$0.80 million$0.29 million
5/6/20213/31/2021($0.24)($0.25)($0.01)($0.30)$2.40 million$0.17 million  
2/25/202112/31/2020($0.24)($0.26)($0.02)($0.31)$0.30 million$0.32 million
11/16/20209/30/2020($0.32)($0.26)+$0.06($0.36)
8/6/2020Q2 2020($0.35)($0.09)+$0.26($0.09)
5/7/20203/31/2020($0.34)($0.32)+$0.02($0.35)$1.20 million
2/26/2020Q4($0.3550)($0.39)($0.0350)($0.43)$1.30 million
11/6/2019Q3 2019($0.32)($0.35)($0.03)($0.35)
8/7/2019Q2 2019($0.45)($0.34)+$0.11($0.34)
5/8/2019Q1 2019($0.36)($0.41)($0.05)($0.41)
2/27/2019Q4 2018($0.53)($0.38)+$0.15($0.38)
11/7/20189/30/2018($0.31)($0.21)+$0.10($0.21)$0.30 million
8/8/2018Q2($0.42)($0.2740)+$0.1460($0.27)$0.30 million
5/16/2018Q1 2018($0.48)($0.42)+$0.06($0.41)
2/28/2018Before Market($0.45)($0.46)($0.01)($0.46)$0.35 million
11/20/2017Before Market($0.52)($0.49)+$0.03($0.49)$0.35 million
8/16/2017Q2 2017($0.53)($0.52)+$0.01($0.52)
5/17/20173/31/2017($0.50)($0.48)+$0.02($0.48)$0.32 million
2/28/2017Q4 2016($0.48)($0.41)+$0.07($0.41)
11/14/2016Q3 2016($0.57)($0.48)+$0.09($0.48)
8/17/2016Q2 2016($0.43)($0.48)($0.05)($0.48)
5/18/2016Q1 2016($0.42)($0.48)($0.06)($0.48)$0.22 million
2/17/2016Q4 2015($0.35)($0.29)+$0.06($0.29)
11/23/2015Q3 2015($0.36)($0.30)+$0.06($0.30)
8/19/2015Q2 2015($0.32)($0.41)($0.09)($0.41)
5/21/2015Q1 2015($0.29)$0.01+$0.30$0.01
2/26/2015Q4 2014($0.27)($0.30)($0.03)($0.30)
11/24/2014Q3 2014($1.00)($0.53)+$0.47($0.53)












ProQR Therapeutics Earnings - Frequently Asked Questions

When is ProQR Therapeutics's earnings date?

ProQR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off last year's report dates. Learn more on PRQR's earnings history.

Did ProQR Therapeutics beat their earnings estimates last quarter?

In the previous quarter, ProQR Therapeutics (NASDAQ:PRQR) reported ($0.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.20) by $0.04. Learn more on analysts' earnings estimate vs. PRQR's actual earnings.

How much revenue does ProQR Therapeutics generate each year?

ProQR Therapeutics (NASDAQ:PRQR) has a recorded annual revenue of $4.25 million.

How much profit does ProQR Therapeutics generate each year?

ProQR Therapeutics (NASDAQ:PRQR) has a recorded net income of -$68.60 million. PRQR has generated -$0.84 earnings per share over the last four quarters.

What is ProQR Therapeutics's EPS forecast for next year?

ProQR Therapeutics's earnings are expected to decrease from ($0.25) per share to ($0.47) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PRQR) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -